Experts outline their clinical approach to identifying treatment failure in patients on initial pharmacologic treatment for OAB and strategies for subsequent treatment selection.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Multicomponent intervention boosts quality of life in overactive bladder patients
March 15th 2024A recent study reveals the efficacy of a cognitive behavior therapy program, showcasing significant improvements in health-related quality of life among women grappling with moderate to severe overactive bladder.
Read More
Optimizing pain management post urogynecologic surgery with restrictive opioid protocol
March 14th 2024A recent study suggests that restrictive opioid prescribing protocols post-urogynecologic surgery are as effective as standard protocols, emphasizing the importance of multimodal analgesia and outpatient follow-up for patient satisfaction.
Read More